Northwestern University is conducting a Phase III clinical trial with Viromed Pharmaceuticals for an investigational drug (VM202) on painful, diabetic peripheral neuropathy in the legs and feet. This drug has been shown to be safe and effective at reducing pain caused by neuropathy through the generation of new blood vessels and nerves.  The basic inclusion/exclusion criteria are as follows:

1. ​​Between 18-75 years old
2. Established history of Type I or II Diabetes Mellitus
3. Painful, peripheral neuropathy in legs and/or feet caused by DM
4. No proliferative diabetic retinopathy
5. No history of cancer within last 5 years

We have provided a brochure with more information about the clinical trial, the drug and how to participate: VMDN-003 Study Brochure

The trial is being conducted at the following locations through January 2018:

• Northwestern University – Chicago, IL
• Nerve and Muscle Center of Texas – Houston, TX
• Diablo Clinical Research – Walnut Creek, CA
• Compass Research – Orlando, FL
• EVMS – Norfolk, VA
• University of Utah – Neurology – Salt Lake, UT
• Neurological Research Institute – Houston, TX
• Clinical Research of West Florida – Tampa, FL
• Center for Clinical Research – Chicago, IL
• University of Kansas – Lawrence, KS
• University of Minnesota – Minneapolis, MN
• University of Florida – Gainesville, FL
• Clinical Trials, Inc. – Little Rock, AR
• Raleigh Neurology Associates – Raleigh, NC
• Innovative Research – Novi, MI
• Arizona Research Center – Phoenix, AZ
• Rainier Clinical Research – Renton, WA
• Richard Cherlin – Los Gatos, CA
• UF Health College Jacksonville – Jacksonville, FL
• Columbia University Medical Center – New York, New York
• Associated Neurologists of Southern Connecticut – Fairfield, CT
• Northern California Research – Sacramento, CA
• Western Washington Medical Group – Seattle, WA

For more information contact:

Benjamin Joslin
Northwestern University
Chicago, IL
(312) 503 -7504
ben.joslin@northwestern.edu
visit www.VM202.com